



Supplementary Figure 1




Supplementary Fig. 1. ANGPTL4 expression in macrophages is regulated by PPARs and hypoxia. (a) *Angptl4*mRNA expression in peritoneal macrophages from WT and *Cd36^{-/-}* mice treated with or without Ac-LDL (120 µg/ml) for 24 h. (b) *Angptl4* mRNA expression in mouse peritoneal macrophages with indicated treatments for 24 h. Right panel shows the expression of *Ldrl* as a control for cholesterol loading. (c) Luciferase activity assay in Raw 264.7 cells transfected with PPAR response element from mouse *Angptl4* linked to firefly luciferase reporter construct along with renilla luciferase vector and incubated with or without indicated treatments for 24 h. Rosiglitazone is used as a positive control for induction of PPAR activity. (d) *Angptl4* mRNA expression in mouse peritoneal macrophages incubated in hypoxic condition (1% O₂) for indicated time points. Glut1 and Nos2 mRNA expression are used as positive controls for hypoxia. (e) mRNA expression of *Angptl4* in mouse peritoneal macrophages incubated with or without chemical inducer of hypoxia cobalt chloride (CoCl₂) for 12 h. Glut1 expression is used as a positive control for CoCl₂ treatment. All data represent the mean ± SEM and are representative of 3 experiments in duplicate. *P ≤ 0.05, Student's t-test.

Supplementary Figure 2



Supplementary Fig. 2. Genotyping of *Ldlr*^{-/-} chimeras with WT or *Angptl4*^{-/-} BM. PCR amplification of *Angptl4* (left panel) and *Ldlr* (right panel) genes. Genomic DNA prepared from peripheral blood of *Ldlr*^{-/-} chimeras with WT or *Angptl4*^{-/-} BM were amplified using specific primers for *Angptl4* or *Ldlr*. In each panel, lanes 1, 2, and 3 are from *Ldlr*^{-/-} chimeras with WT BM, lanes 4, 5, and 6 are from *Ldlr*^{-/-} chimeras with *Angptl4*^{-/-} BM, lane 7 is from WT and lane 8 from *Angptl4*^{-/-} (left) or *Ldlr*^{-/-} (right).

Supplementary Figure 3





Supplementary Fig. 3. $Angptl4^{-/-}$ bone marrow recipient female $Ldlr^{-/-}$ mice develop bigger atherosclerotic plaques.


(a) Representative histological analysis of cross-sections of the aortic sinus from female Ldr chimeras with WT or $Angptl4^{-/-}$ bone marrow (BM) after 12 weeks of WD stained with H&E and Oil Red O. Quantification is shown in the right panel of respective figure (mean \pm SEM; n=10 per group; *P<0.05, Student's t-test). Total circulating cholesterol (b), plasma triglyceride level (c) and body weight (d) of female $Ldlr^{-/-}$ chimeras with WT or $Angptl4^{-/-}$ BM before and after 12 weeks on WD (mean \pm SEM; n=10 per group). Scale bars = 400 μm .

Supplementary Figure 4

a




b




Supplementary Fig. 4. Hematopoietic *Angptl4* deficiency does not influence gut inflammation and body weight in *Ldlr*^{-/-} mice.

(a) Representative histological analyses of cross-section of the ileum from *Ldlr*^{-/-} chimeras with WT and *Angptl4*^{-/-} BM stained with H&E and CD68 after 12 weeks on WD. Scale bars: 400 µm. (b) Body weight of male *Ldlr*^{-/-} chimeras with WT or *Angptl4*^{-/-} BM before and after 12 weeks on WD (mean ± SEM; n=9 per group).




Supplementary Fig. 5. ANGPTL4 deficiency promotes M1 polarization of macrophages. (a) mRNA expression of indicated M1 and M2 macrophage polarization genes in bone marrow derived macrophages (BMDM) isolated from WT and *Angptl4*^{-/-} mice and treated with LPS/IFNg (M1) or IL-4 (M2) for 8 h (mean \pm SEM, n>3; *P<0.05, Student's t-test). (b) Western blot analysis of indicated proteins from WT and *Angptl4*^{-/-} BMDMs treated with LPS/IFNg. (c) Western blot analysis of indicated proteins from WT and *Angptl4*^{-/-} BMDMs treated with LPS/IFNg for indicated time points. Quantifications are shown in the lower panels. Full scans of Westerns blots are provided in Supplementary Fig. 9.

Supplementary Figure 6



Supplementary Fig. 6. ANGPTL4 deficiency does not influence monocyte migration. (a and b) Migration of BMDMs from adult WT or *Angptl4*^{-/-} mice towards MCP-1 (100 ng/ml) using Boyden chamber assay after 16 hours of incubation (mean ± SEM; n=4 in duplicates) (a) and Real-time Cell Invasion and Migration (RT-CIM) x CELLigence assay system (mean ± SEM; n=3 in quadruples) (b). (c) Representative histogram of the flow cytometry analysis of CCR2 expression in blood monocytes isolated from *Ldlr*^{-/-} mice transplanted with WT and *Angptl4*^{-/-} BM and put on WD for 3 months. Quantification of geometric mean intensity from all experiments is on the right panel (mean ± SEM; n=5 per group).

Supplementary Figure 7



Supplementary Figure 7. Original gel scans for **Fig. 1h**

Supplementary Figure 8

Fig 7f, original western blots






Fig 7g, original western blots



Supplementary Figure 8. Original gel scans for **Fig. 7f** and **Fig 7g**

Supplementary Figure 9



Supplementary Figure 9. Original gel scans for **Supplemental Fig. 5b**

Supplementary Table 1

Mouse primer sequence

Primer	Forward sequence	Reverse sequence
18S	5'-ttccgataacgaacgagactc-3'	5'-tggctgaacgccacttgtc-3'
Angptl4	5'-caccaatgttccccaaat-3'	5'-aagataaccctttacgcctcg-3'
Ear2	5'-gtggccctcaccgagtgatg-3'	5'-ggctcgatgggtctgc-3'
F7	5'-aaaggcgtgccaactcactc-3'	5'-cctacgttgcacatggattcg-3'
Syn1	5'-agctaacaatcccagtctc-3'	5'-cggatggtctcagttcac-3'
Igf1	5'-gcattgtggatgagggtgtgc-3'	5'-ggctcccttacatttgta-3'
Lipn	5'-gggtacattctgcaccaac-3'	5'-ctcaagccagtaggcattgtc-3'
Adssl1	5'-ctcacctgtgtcacttcc-3'	5'-agcaaagcccttgcaccc-3'
Adam8	5'-agttcctgttatgccccaaag-3'	5'-aaagggtggcttgcacctgct-3'
Hyal1	5'-cctcaaccctgcccagtctc-3'	5'-cccgcttgtcacaccactt-3'
Acca2	5'-ctgctacgagggtgttcatc-3'	5'-agctctgcacatggccc-3'
Abca1	5'-ggttggagatggttatacaatagtgt-3'	5'-cccgaaacgcaagtcc-3'
Abcg1	5'-tcacccagttctgcaccc-3'	5'-gcagatgtcaggaccgagt-3'
Cd36	5'-tcctctgacattgcaggctatc-3'	5'-aaaggcattggctgaaagaa-3'
Ldlr	5'-ggtactggcaaccaccattggg-3'	5'-gccaatcgactcacgggttcag-3'
Nos2	5'-cagctggctgtacaaaccc-3'	5'-cattggaagtgaagcgttcg-3'
Glut1	5'-cagttcggctataacactgg-3'	5'-ccccccgacagagaagatg-3'
Cox-2	5'-acctctccaccaatgacgtg-3'	5'-gggagagagttcatccctga-3'
Tnfa	5'-ccctcacactcagatcatctc-3'	5'-gctacgacgtggctacag-3'
Il-12b	5'-ggaagcacggcagcagaata-3'	5'-aacttgagggagaagtaggaatgg-3'
Ym1	5'-gcagaagctccagaagcaatctg-3'	5'-attggcctgtccatggccaaactg-3'
Arg1	5'-ttgggtggatgctcacactg-3'	5'-ttgcccattgcagattccc-3'
Mcp-1	5'-actcattcaccagcaagatg-3'	5'-tgtaggtctgatctattgg-3'
Cd68	5'-ccaattcagggtgaaagaaa-3'	5'-ctcggcctgtatgttaggtc-3'
Hmgcr	5'-cttgttggaatgccttgtattg-3'	5'-agccgaagcagcacatgat-3'
Il-6	5'-agttgccttctggactga-3'	5'-tccacgattcccagagaac-3'
Ccl3	5'-ttctctgtaccatgacactctgc-3'	5'-cgttggaaatctccggctgttag-3'
Icam-1	5'-ctcggagacattagagaacaatgc-3'	5'-gggaccacggagccaatt-3'
Vcam-1	5'-gcgttagtggctgttatctg-3'	5'-ctgaataaaaaacgatcgctcaa-3'
Sele	5'-agctaccatggAACACGAC-3'	5'-cgcaagttctccagctgtt-3'

Human primer sequence

ANGPTL4	5'-ctccacttggaccaggatca-3'	5'-atggctgcagggtccaaac-3'
ABCA1	5'-ggtgtatgtttctgcaccaatgtga-3'	5'-tgtcctcataccagttgagagac-3'
HMGCR	5'-gtcattccagccaaagggtgt-3'	5'-gggaccactgtctccattta -3'

Genotyping primers

Angptl4	P1	5'-gtgcaaccgtgaaacgctta-3'
	P2	5'-agccagcaagttcatctcg-3'
	P3	5'-gacagtatcggcctcaggaa-3'
Ldlr	P1	5'-gcgatggatacactcactgc-3'
	P2	5'-aatccatcttgttcaatggccgatc-3'
	P3	5'-ccatatgcatccccagtctt-3'

Supplementary Table 1. PCR primer sequences